Guardant Health, Inc. CEO Helmy Eltoukhy described the recent US Food and Drug Administration approval of the company’s liquid biopsy test Guardant360 CDx as a “watershed moment for comprehensive liquid biopsy” because it provides oncologists with the information they need to close the gap between clinical guidelines and clinical practice.
The Redwood City, CA-based liquid biopsy company announced on 7 August that its Guardant360 assay was approved for comprehensive tumor mutation profiling across any solid tumor cancers and as a companion diagnostic to identify non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) alterations
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?